These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38622428)

  • 21. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association between the lymphocyte-monocyte ratio and disease activity in rheumatoid arthritis.
    Du J; Chen S; Shi J; Zhu X; Ying H; Zhang Y; Chen S; Shen B; Li J
    Clin Rheumatol; 2017 Dec; 36(12):2689-2695. PubMed ID: 28913574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis.
    Chandrashekara S; Rajendran A; Bai Jaganath A; Krishnamurthy R
    Reumatismo; 2015 Dec; 67(3):109-15. PubMed ID: 26876190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab.
    Zhou L; Xiao DM; Qin W; Xie BH; Wang TH; Huang H; Zhao BJ; Han X; Sun QQ; Wu XD; Cen H
    J Clin Lab Anal; 2019 Jun; 33(5):e22862. PubMed ID: 30779461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio and red blood cell distribution width in distinguishing between reactive lymphadenopathy and lymphoma in children.
    Tezol O; Bozlu G; Sagcan F; Tuncel Daloglu F; Citak C
    Bratisl Lek Listy; 2020; 121(4):287-292. PubMed ID: 32356444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma.
    Kara M; Uysal S; Altinişik U; Cevizci S; Güçlü O; Dereköy FS
    Eur Arch Otorhinolaryngol; 2017 Jan; 274(1):535-542. PubMed ID: 27520567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Red Blood Cell Distribution Width in Rheumatoid Arthritis, Ankylosing Spondylitis and Osteoarthritis: True Inflammatory Index or Effect of Anemia?
    Lin F; Wang X; Liang Y; Liu D; Zhang Y; Zhong R; Yang Z
    Ann Clin Lab Sci; 2018 May; 48(3):301-307. PubMed ID: 29970432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.
    Farutin V; Prod'homme T; McConnell K; Washburn N; Halvey P; Etzel CJ; Guess J; Duffner J; Getchell K; Meccariello R; Gutierrez B; Honan C; Zhao G; Cilfone NA; Gunay NS; Hillson JL; DeLuca DS; Saunders KC; Pappas DA; Greenberg JD; Kremer JM; Manning AM; Ling LE; Capila I
    Arthritis Res Ther; 2019 Oct; 21(1):216. PubMed ID: 31647025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of hematologic markers with IL-17 and IL-1 beta in patients with rheumatoid arthritis.
    Sağ S; Sağ MS; Tekeoğlu I; Kamanlı A; Nas K; Acar BA
    J Back Musculoskelet Rehabil; 2018; 31(4):703-707. PubMed ID: 29578474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
    Guo X; Wang S; Godwood A; Close D; Ryan PC; Roskos LK; White WI
    Int J Rheum Dis; 2019 Apr; 22(4):646-653. PubMed ID: 30358109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.
    Uslu AU; Küçük A; Şahin A; Ugan Y; Yılmaz R; Güngör T; Bağcacı S; Küçükşen S
    Int J Rheum Dis; 2015 Sep; 18(7):731-5. PubMed ID: 25900081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.